Csl Seqirus was Arcturus Therapeutics Holdings’s largest revenue line in fiscal 2025, bringing in $65.98M of $82.03M (80%).
| Counterparty Name | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Csl Seqirus | $154.43M | $154.26M | $138.39M | $65.98M | ||||
| Vinbiocare | $24.57M | — | — | — | ||||
| Israel Ministry Of Health | $12.50M | — | — | — | ||||
| Barda | $244.00K | $9.05M | $13.92M | $13.24M | ||||
| Collaboration Partner - Ultragenyx | — | — | — | — | ||||
| Janssen | $9.20M | — | — | — | ||||
| Collaboration Partner - Curevac | — | — | — | — | ||||
| Curevac | — | — | — | — | ||||
| Ultragenyx | $3.74M | $1.84K | — | — | ||||
| Collaboration Partner – Other | — | — | — | — | ||||
| Sgi | — | — | — | — | ||||
| Gates Foundation | — | — | — | $1.57M | ||||
| Other | $1.32M | $1.65M | — | $1.24M | ||||
| Collaboration Partner - Sgi | — | — | — | — | ||||
| Collaboration Partner Janssen | — | — | — | — | ||||
| Total | $206.00M | $164.96M | $152.31M | $82.03M |
Arcturus Therapeutics Holdings brought in $82.03M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Arcturus Therapeutics Holdings regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $152.31M. Csl Seqirus was the largest at $65.98M (80.4%), ahead of Barda at $13.24M (16.1%) and Gates Foundation at $1.57M (1.9%). The remaining revenue line, Other, brought in $1.24M.
Compared with fiscal 2024, Barda fell 4.9% to $13.24M and Csl Seqirus fell 52.3% to $65.98M.
Arcturus Therapeutics Holdings began breaking out Gates Foundation in fiscal 2025, when it brought in $1.57M. Arcturus Therapeutics Holdings stopped reporting Vinbiocare ($24.57M in fiscal 2022), Israel Ministry Of Health ($12.50M in fiscal 2022), Janssen ($9.20M in fiscal 2022) and one other as separate revenue lines.
Collaboration Revenue was Arcturus Therapeutics Holdings’s largest product and service line in fiscal 2025, bringing in $65.98M of $79.22M (83%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Collaboration Revenue | $179.00M | $157.75M | $138.39M | $65.98M | |
| Grant Revenue | $244.00K | $9.05M | $13.92M | $13.24M | |
| Total | $179.24M | $166.80M | $152.31M | $79.22M |
Arcturus Therapeutics Holdings brought in $79.22M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 48.0% from $152.31M in fiscal 2024. Collaboration Revenue was the largest at $65.98M (83.3%), ahead of Grant Revenue at $13.24M (16.7%).
Compared with fiscal 2024, Grant Revenue fell 4.9% to $13.24M and Collaboration Revenue fell 52.3% to $65.98M. From fiscal 2022 to 2025, combined revenue from these lines fell from $179.24M to $79.22M, a compound annual decline of 23.8%. Collaboration Revenue's share of the total fell from 99.9% to 83.3%.
Arcturus Therapeutics Holdings (ARCT) reports its revenue by counterparty name and by product and service. In fiscal 2025, Csl Seqirus was its largest revenue line, bringing in $65.98M (80.4% of the total), followed by Barda at $13.24M (16.1%).
Csl Seqirus was Arcturus Therapeutics Holdings' largest revenue line in fiscal 2025, bringing in $65.98M, or 80.4% of the $82.03M total across its four revenue lines.
Collaboration Revenue was Arcturus Therapeutics Holdings' largest product and service line in fiscal 2025, bringing in $65.98M, or 83.3% of the $79.22M total across its two product and service lines.
Every figure comes from Arcturus Therapeutics Holdings' annual financial filings, as reported. Each line keeps the name Arcturus Therapeutics Holdings gives it, and years follow its fiscal calendar.
Arcturus Therapeutics Holdings' revenue by counterparty name goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.